GLP1R as a Radioligand Therapy Target
GLP1R, glucagon like peptide 1 receptor, is a cell-surface protein (GPCR). No tumor protein staining is recorded for it in Human Protein Atlas immunohistochemistry. Evidence on whether GLP1R internalizes is mixed. Clinical status: Clinical-stage (up to phase 3, any modality).
Is GLP1R a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ❌ Tumor expression: No tumor staining in HPA immunohistochemistry.
- ⚠️ Internalization: Mixed evidence.
- ✅ Clinical precedent: Clinical-stage (up to phase 3, any modality)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
GLP1R expression in cancer
No Human Protein Atlas tumor immunohistochemistry data is available for GLP1R.
Is GLP1R internalized?
Uncertain. Insufficient literature found.
Sources: PMID 41463424 · PMID 41381542 · PMID 41319798 · PMID 41100251 · PMID 40831316. AI-extracted from abstracts, so verify before citing.
GLP1R clinical trials
Clinical-stage (up to phase 3, any modality). Nuclens hasn't indexed trials for GLP1R yet. Search ClinicalTrials.gov for GLP1R trials.
GLP1R normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See GLP1R in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
GLP1R gene essentiality (DepMap)
CRISPR knockout effect across 1233 cancer cell lines: 0.12 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
See how GLP1R ranks against 15,000 targets for your indication.
Run a free analysisData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.